Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989–2004

OBJECTIVE. Our goal was to determine trends in low birth weight and preterm birth among US infants born to HIV-infected women. METHODS. We used data from the longitudinal Pediatric Spectrum of HIV Disease, a large HIV cohort, to assess trends in low birth weight and preterm birth from 1989 to 2004 among 11321 study infants. Among women with prenatal care, we also assessed risk factors, including maternal antiretroviral therapy during pregnancy, that were predictive of low birth weight and preterm birth using univariate and multivariate logistic regression models. RESULTS. Overall, 11231 of 14464 infants who were enrolled in Pediatric Spectrum of HIV Disease were tested during the neonatal period. From 1989 to 2004, testing increased from 32% to 97%. The proportion of HIV-exposed infants who had low birth weight decreased from 35% to 21% and occurred in all racial/ethnic groups. Prevalence of preterm birth decreased from 35% to 22% and occurred in all groups. Any maternal antiretroviral therapy use increased from 2% to 84%. Among 8793 women who had prenatal care, low birth weight was associated with a history of illicit maternal drug use, unknown maternal HIV status before delivery, symptomatic maternal HIV disease, black race, Hispanic ethnicity, and infant HIV infection. Antiretroviral therapy or lack of it was not associated with low birth weight. Among women with prenatal care, preterm birth was associated with a history of illicit maternal drug use, symptomatic maternal HIV disease, no antiretroviral therapy, receipt of a 3-drug highly active antiretroviral therapy regimen with protease inhibitors, black race, and infant HIV infection. CONCLUSIONS. The proportion of infants who had low birth weight or were born preterm declined during an era of increased maternal antiretroviral therapies. These Pediatric Spectrum of HIV Disease trends differ from the overall increases in both outcomes among the US population.

[1]  B. Luke,et al.  Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? , 2006, The Journal of infectious diseases.

[2]  J. Martin,et al.  Births: preliminary data for 2004. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[3]  C. Zorrilla,et al.  Protease Inhibitor Use in 233 Pregnancies , 2005, Journal of acquired immune deficiency syndromes.

[4]  D. H. Watts,et al.  Improved Obstetric Outcomes and Few Maternal Toxicities Are Associated With Antiretroviral Therapy, Including Highly Active Antiretroviral Therapy During Pregnancy , 2005, Journal of acquired immune deficiency syndromes.

[5]  M. Newell,et al.  Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe , 2004, AIDS.

[6]  J. Bartlett,et al.  Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to reduce Perinatal HIV-1Transmission in the United States , 2003 .

[7]  Jeffrey L. Jones,et al.  Trends in Pregnancy Rates Among Women With Human Immunodeficiency Virus , 2004, Obstetrics and gynecology.

[8]  C. Benedetto,et al.  INCREASED RISK OF ADVERSE PREGNANCY OUTCOMES IN HIV-INFECTED WOMEN TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN EUROPE , 2004 .

[9]  M. Lindegren,et al.  Increasing Trend of Cesarean Deliveries in HIV‐Infected Women in the United States From 1994 to 2000 , 2003, Journal of acquired immune deficiency syndromes.

[10]  M. Newell,et al.  Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. , 2003, Journal of acquired immune deficiency syndromes.

[11]  Deren Bader,et al.  US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, hispanics, and blacks. , 2003, Pediatrics.

[12]  J. Church.  Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1 , 2002, Pediatrics.

[13]  M. Hughes,et al.  Antiretroviral therapy during pregnancy and the risk of an adverse outcome. , 2002, The New England journal of medicine.

[14]  K. Schoendorf,et al.  Changing patterns of low birthweight and preterm birth in the United States, 1981-98. , 2002, Paediatric and perinatal epidemiology.

[15]  M. Lindegren,et al.  Trends in HIV testing among pregnant women: United States, 1994-1999. , 2001, American journal of public health.

[16]  Swiss Mother.  Combination antiretroviral therapy and duration of pregnancy , 2000, AIDS.

[17]  K. Ethier,et al.  Infant birth weight among women with or at high risk for HIV infection: the impact of clinical, behavioral, psychosocial, and demographic factors. , 2000, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[18]  D. Harris,et al.  Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine , 2000, AIDS.

[19]  J. Ward,et al.  Trends in perinatal transmission of HIV/AIDS in the United States. , 1999, JAMA.

[20]  J. Read,et al.  The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies: the International Perinatal HIV Group , 1999 .

[21]  F. Parazzini.  Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial , 1999, The Lancet.

[22]  J. Pitt,et al.  Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  P. Falconieri,et al.  The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 , 1999 .

[24]  B. Hirschel,et al.  Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects , 1998, AIDS.

[25]  P Bacchetti,et al.  Risk of Low Birth Weight Infants Among Black and White Parents , 1998, Obstetrics and gynecology.

[26]  W. Hauck,et al.  Improved Birth Outcomes Associated With Enhanced Medicaid Prenatal Care in Drug‐Using Women Infected With the Human Immunodeficiency Virus , 1998, Obstetrics and gynecology.

[27]  R. Steketee,et al.  Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV , 1998, AIDS.

[28]  R. Sperling,et al.  Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. , 1997, The Journal of pediatrics.

[29]  V. Rauh,et al.  Ethnic differences in birthweight: the role of lifestyle and other factors. , 1997, American journal of public health.

[30]  L. Markson,et al.  Association of maternal HIV infection with low birth weight. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[31]  W. Hauck,et al.  Prenatal care and birth outcomes of a cohort of HIV-infected women. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[32]  L. Kalish,et al.  Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child , 1996, The New England journal of medicine.

[33]  H. Barnhart,et al.  Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. , 1996, Pediatrics.

[34]  Reduction of maternal‐infant transmission of human immunodeficiency virus type 1 with zidovudine treatment , 1995 .

[35]  D. Satcher.  U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[36]  N. Day,et al.  The Epidemiology of Alcohol, Marijuana, and Cocaine Use Among Women of Childbearing Age and Pregnant Women , 1993, Clinical obstetrics and gynecology.

[37]  S. Seiden,et al.  Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. , 1993, Journal of acquired immune deficiency syndromes.

[38]  J. Desenclos,et al.  Characteristics of mothers of live infants with congenital syphilis in Florida, 1987-1989. , 1992, American journal of epidemiology.

[39]  M C McCormick,et al.  The contribution of low birth weight to infant mortality and childhood morbidity. , 1985, The New England journal of medicine.

[40]  R. Plackett,et al.  Principles of regression analysis , 1961 .